Trial · NCT01415440
Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD
NCT01415440, Not applicable, Completed, New York State Psychiatric Institute; results first posted 2019-09-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD. Trials, record NCT01415440. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01415440
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD
- NCT number
- NCT01415440
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 117 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Lisdexamfetamine, Placebo
- First posted
- 2011-08-12
- Last updated
- 2022-08-02
- Results first posted
- 2019-09-11
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Brain Structure Volume | 12 weeks | Brain structure volume measured in mm\^3 |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Brain Structure Volume | 12 weeks | ADHD participants who completed 12 weeks of treatment. | mm^3 | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Brain Structure Volume | ADHD - Placebo | Left Hippocampal Volume | 3909.85 | Standard Deviation 535.35 | mm^3 |
| Brain Structure Volume | ADHD - Vyvanse | Left Hippocampal Volume | 4069.72 | Standard Deviation 426.46 | mm^3 |
| Brain Structure Volume | ADHD - Placebo | Left Amygdala Volume | 1431.31 | Standard Deviation 245.40 | mm^3 |
| Brain Structure Volume | ADHD - Vyvanse | Left Amygdala Volume | 1485.05 | Standard Deviation 235.17 | mm^3 |
| Brain Structure Volume | ADHD - Placebo | Right Hippocampal Volume | 4048.10 | Standard Deviation 454.37 | mm^3 |
| Brain Structure Volume | ADHD - Vyvanse | Right Hippocampal Volume | 4206.41 | Standard Deviation 413.38 | mm^3 |
| Brain Structure Volume | ADHD - Placebo | Right Amygdala Volume | 1573.57 | Standard Deviation 240.03 | mm^3 |
| Brain Structure Volume | ADHD - Vyvanse | Right Amygdala Volume | 1641.88 | Standard Deviation 207.45 | mm^3 |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Healthy Control | 41 | |
| Overall Study | STARTED | ADHD - Placebo | 29 | |
| Overall Study | STARTED | ADHD - Vyvanse | 29 | |
| Overall Study | COMPLETED | Healthy Control | 37 | |
| Overall Study | COMPLETED | ADHD - Placebo | 28 | |
| Overall Study | COMPLETED | ADHD - Vyvanse | 27 | |
| Overall Study | NOT COMPLETED | Healthy Control | 4 | |
| Overall Study | NOT COMPLETED | ADHD - Placebo | 1 | |
| Overall Study | NOT COMPLETED | ADHD - Vyvanse | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Healthy Control | 0 | 41 |
| Total, all-cause mortality | ADHD - Placebo | 0 | 29 |
| Total, all-cause mortality | ADHD - Vyvanse | 0 | 29 |
| Total, other adverse events | Healthy Control | 0 | 41 |
| Total, other adverse events | ADHD - Placebo | 0 | 29 |
| Total, other adverse events | ADHD - Vyvanse | 0 | 29 |
| Total, serious adverse events | Healthy Control | 0 | 41 |
| Total, serious adverse events | ADHD - Placebo | 0 | 29 |
| Total, serious adverse events | ADHD - Vyvanse | 0 | 29 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35141898 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01415440
GET https://conductscience.org/api/trials/v1/NCT01415440/registered